Evidence map›Paper›PMID 41221269›Full record

ArticleCancer heterogeneity and plasticity2025

Advancing Cancer Biology: Highlights from the 2025 FASEB SRC on Cellular Plasticity in Cancer.

Hans Clevers, Ankur Sharma, Sendurai A Mani, Anna Golebiewska, Axel Behrens, Wai Leong Tam, Loic P Deleyrolle, Huiping Liu, Karuna Ganesh, Walid T Khaled and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer heterogeneity and plasticity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hans CleversPharma, Research and Early Development (pRED) of F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Ankur SharmaTranslational Genomics Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Sendurai A ManiDepartment of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.
Anna GolebiewskaNORLUX Neuro-Oncology Laboratory, Department of Cancer Research, Luxembourg Institute of Health, L-1210 Luxembourg, Luxembourg.
Axel BehrensCancer Stem Cell Laboratory, The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Wai Leong TamGenome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome, Singapore, 138672, Singapore.
Loic P DeleyrolleDepartment of Molecular Medicine, Mayo Clinic, Jacksonville, FL, 32224, USA.
Huiping LiuCirculating Tumor Cell Core, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Karuna GaneshMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Walid T KhaledDepartment of Pharmacology, University of Cambridge, Cambridge, UK.
Shaheen SikandarDepartment of Molecular, Cell and Developmental Biology, University of California - Santa Cruz, Santa Cruz, CA, 95064, USA.
Terence K LeeDepartment of Applied Biology and Chemical Technology, Hong Kong Polytechnic University, Hong Kong SAR, China.
Tyler E MillerDepartment of Pathology, Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center, Cleveland, OH, 44106-7285, USA.
Dean G TangDepartment of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Sheila SinghDepartment of Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada.
Vivian S W LiStem Cell and Cancer Biology Laboratory, The Francis Crick Institute, London, UK.
Justin D LathiaDepartment of Cardiovascular & Metabolic Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH 44195, USA.
Stephanie MaSchool of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

Funding

Novel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa CellsR01CA240290 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 2019 to 2026
$3.1M
Metabolic interactions between tumor cells and the immune system in GBM: A potential Achilles heel of GBM for novel therapeuticsR01NS121075 · NINDS · UNIVERSITY OF FLORIDA · PI DELEYROLLE, LOIC PIERRE · 2022 to 2025
$1.6M
Molecular mechanisms regulating LMO2+ metastasis initiating cellsR37CA269754 · NCI · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI Shaheen Sikandar · 2023 to 2026
$1.4M
Targeting myeloid cells to increase efficacy of immunotherapy against brain tumors.K08CA276819 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Tyler Eugene Miller · 2023 to 2026
$846k
NCI NIH HHS K08 CA276819NCI NIH HHS R01 CA240290NCI NIH HHS R37 CA269754NINDS NIH HHS R01 NS121075
6 · The paper itself

Abstract

The inaugural FASEB Science Research Conference (SRC) on Cellular Plasticity in Cancer was held in May 2025 in Hong Kong SAR, China. This event brought together leading experts to discuss cutting-edge research centered on cancer cell plasticity. The conference featured comprehensive presentations covering a broad spectrum of topics, including oncofetal reprogramming in tumor development and progression, mechanisms regulating cancer cell plasticity, metabolic reprogramming and its role in tumor progression, cancer cell plasticity during metastasis, cancer stem cell programs within the tumor microenvironment, tumor plasticity and immune evasion, as well as innovative therapeutic strategies aimed at targeting stem cell-like states, modulating cancer cell states, and effectively controlling disease progression. It is anticipated that the insights gained from this meeting will catalyze further advancements in cancer biology and therapy.

Indexed as

cancer cell plasticitycancer stem cellscellular plasticityimmune evasionphenotypic switchingtherapy resistancetumor microenvironment

Identifiers

PMID41221269
PMCPMC12599846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.